Trial Profile
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Rimiducid (Primary) ; Rivogenlecleucel (Primary)
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 01 Oct 2020 Planned End Date changed from 1 Feb 2035 to 1 May 2034.
- 01 Oct 2020 Planned primary completion date changed from 1 Feb 2020 to 1 May 2021.
- 24 Oct 2019 Planned End Date changed from 1 Feb 2021 to 1 Feb 2035.